Aquestive Therapeutics (AQST) announced that Health Canada has granted the Company a meeting to discuss Aquestive’s planned New Drug Submission for Anaphylm Sublingual Film in Canada. In addition, the Company has submitted an initial briefing book to the European Medicines Agency. The Company plans to submit a Marketing Authorization Application to the EMA as soon as possible. The Company’s ex-U.S. regulatory strategy prioritizes markets with significant unmet medical needs and regulatory frameworks conducive to innovative therapies. EMA and Canada represent ideal initial international markets given their collaborative regulatory environment and substantial population of patients requiring reliable anaphylaxis treatment options. Aquestive will continue to provide updates on its global regulatory approval progress as it works to establish Anaphylm as the new standard of care for the treatment of severe allergic reactions and anaphylaxis worldwide.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics announces two presentations on Anaphylm
- Positive Outlook for Aquestive Therapeutics Amidst FDA Progress and Strategic Preparations for Anaphylm Launch
- Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Progress and Market Potential
- FDA Accepts Aquestive’s New Drug Application for Anaphylm
- Aquestive announces FDA acceptance of NDA, PDUFA date for Anaphylm